# Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis

> **NCT02555800** · PHASE2 · UNKNOWN · sponsor: **Centro de Investigación en. Enfermedades Infecciosas, Mexico** · enrollment: 36 (estimated)

## Conditions studied

- Recurrent Respiratory Papillomatosis

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Cidofovir
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02555800
- **Lead sponsor:** Centro de Investigación en. Enfermedades Infecciosas, Mexico
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-12
- **Primary completion:** 2016-12
- **Final completion:** 2017-06
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2016-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02555800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02555800, "Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02555800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*